Last reviewed · How we verify
TS23
At a glance
| Generic name | TS23 |
|---|---|
| Sponsor | Translational Sciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Strategy for Improving Stroke Treatment Response (PHASE2)
- Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial (PHASE2)
- DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE) (PHASE2)
- Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TS23 CI brief — competitive landscape report
- TS23 updates RSS · CI watch RSS
- Translational Sciences, Inc. portfolio CI